Eyenovia, Inc. vs Sydnexis, Inc.

Patent Owner's Notice of Appeal

Final Written Decision: original

Other: Hearing transcript

Order: Panel Change Order

Petitioner's Demonstratives for Oral Argument

Petitioner's Updated Exhibit List

Patent Owner's Demonstratives

Patent Owner's Reply ISO Motion to Exclude Evidence

Petitioner's Updated Exhibit List

Petitioner’s Opposition to Patent Owner’s Motion to Exclude Evidence

Excerpts of Sambrook & Russell, Molecular Cloning: A Laboratory Manual, (3d ed., 2001)

Excerpts of “4.1.3 BUFFER SOLUTIONS” from European Pharmacopoeia, (5th ed., 2004)

“Calbiochem® Buffers: A guide for the preparation and use of buffers in biological systems,” University of North Carolina School of Medicine Department of Pharmacology

MilliporeSigma web page titled “Buffer Reference Center”

NIH National Library of Medicine PubChem web page titled “Monosodium phosphate”

NIH National Library of Medicine PubChem web page titled “Disodium hydrogen phosphate”

Declaration of Rebecca L. Baker

Patent Owner's Motion to Exclude Evidence

ORDER Setting Oral Argument 37 C.F.R. sec 42.70

Petitioner's Request for Oral Argument

Patent Owner's Request for Oral Argument

Patent Owner's Updated Mandatory Notices

Patent Owner's Sur-Reply

Petitioner's Notice of Supplemental Evidence

Patent Owner's Objections to Evidence

Petitioner's Reply to Patent Owner's Response

Freedom of Information Act (FOIA) Request No. 58532 filed with National Library of Medicine on August 7, 2022 and automated response.

National Library of Medicine Freedom of Information Act (FOIA) Request No. 58532 and August 8, 2022 response.

December 9, 2022, Deposition Transcript of Paul A. Laskar, Ph.D.

Appendix 1: 1 Preparation of Reagents and Buffers Used in Molecular Cloning, in Sambrook, J. F., & Russell, D. W., Molecular cloning: A laboratory manual (3d ed. 2001).

United States Patent Publication No. 2011/0184017 Al to Kanzawa et al.

Chapter 4: Reagents, in Directorate for the Quality of Medicine & Health Care of the Council of Europe (EDQM), European Pharmacopoeia (5th ed. 2004)

Buffers: A guide for the preparation and use of buffers in biological systems, Calbiochem (2006), available at https://www.med.unc.edu/pharm/sondeklab/wp-content/uploads/sites/868/2018/10/buffers_calbiochem.pdf (last visited Dec. 5, 2022).

Buffer Reference Center, MilliporeSigma, available at https://www.sigmaaldrich.com/US/en/technical-documents/protocol/protein-biology/protein-concentration-and-buffer-exchange/buffer-reference-center (last visited Dec. 5, 2022).

Monosodium phosphate, PubChem, available at https://pubchem.ncbi.nlm.nih.gov/compound/Monosodium-phosphate#section=pH (last visited Dec. 5, 2022).

Disodium hydrogen phosphate, PubChem, available at https://pubchem.ncbi.nlm.nih.gov/compound/24203#section=Refractive-Index (last visited Dec. 5, 2022).

Declaration of Dr. Paul A. Laskar Ph.D (Ex. 1014) in IPR2018-01020, executed on May 14, 2018.

U.S. Patent No. 8,791,154 to Gamache et al., (Ex. 1001 in IPR2018-01020).

U.S. Patent No. 6,995,186 B2 to Castillo et al., (Ex. 1005 in IPR2018-01020).

Petitioner's Notice of Deposition of Paul A. Lasker, Ph.D.

Patent Owner's Response

October 21, 2022, Declaration of Paul A. Laskar, Ph.D.

September 30, 2022, Deposition Transcript of Dr. Stephen R. Byrn

Silvergate Pharmaceuticals, Inc. v. Bionpharma Inc., Case Nos. 18-1962-LPS, 19-1067-LPS, April 27, 2021Trial Decision, D.I. 294, D.I. 307 (D. Del. Aug. 2, 2021)

Reckitt Benckiser Inc. v. Tris Pharma, Inc., Case No. 09-3125-FLW, Decision on Summary Judgment, D.I. 220 (D.N.J. Dec. 2, 2011)

ORDER Granting Petitioners Unopposed Motions for Admission Pro Hac Vice of Thomas H. Wintner 37 C.F.R. sec 42.10

Updated Byrn Deposition Notice

Notice of Deposition of Stephen R. Byrn, Ph.D.

Joint Stipulation to Modify the Scheduling Order

Petitioner's Notice of Supplemental Evidence

UNOPPOSED MOTION FOR PRO HAC VICE ADMISSION OF THOMAS H. WINTNER

DECLARATION OF THOMAS H. WINTNER

Patent Owner's Objections to Evidence

Petitioner's Updated Mandatory Notices

DECISION Granting Institution of Inter Partes Review 35 U.S.C. 314

SCHEDULING ORDER

Patent Owner's Sur-Reply

Exhibit 3001

Petitioner's Reply to Patent Owner's Preliminary Response

FDA Approval Package for Akorn Inc., Atropine Sulfate Ophthalmic Solution, USP, 1%, available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206289Orig1s000Approv.pdf (last visited 5/12/2022)

DailyMed database webpages for ATROPINE (atropine sulfate) solution/ drops, Akorn Inc., available at https://dailymed.nlm.nih.gov/dailymed/ (sites last visited 5/12/2022)

August 4, 2017 FDA Pediatric Postmarketing Pharmacovigilance and Drug Utilization Review for NDA 206289 (Akorn Inc., Atropine Sulfate Ophthalmic Solution, USP 1%)

Patent Owner's Preliminary Response

EX2001 - Laskar Declaration

EX2002 - Laskar CV

EX2004 - PAIR - PAIRPrintServlet

EX2005 - Internet Archives Affidavit

EX2006 - Amneal Pharms FDA Page

EX2007 - Apotex FDA Page 215624

EX2008 - Intl Medication Sys FDA Page

Notice: Notice filing date accorded

Patent Owner's Mandatory Notices

Patent Owner's Power of Attorney

Petition for Inter Partes Review of U.S. Patent No. 10,842,787

Petitioner's Power of Attorney

U.S. Patent No. 10,842,787 to Ostrow et al.

Declaration of Dr. Stephen Byrn, Ph.D.

Chia et al., Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2), OPHTHALMOLOGY 119(2): 347���354 (2012)

Akorn Atropine CareTM (atropine sulfate ophthalmic solution), NDA 206289 Product Label (Revised July 2014)

Albert A. Kondritzer & Peter Zvirblis, Stability of Atropine in Aqueous Solution, J. AM. PHARM. ASSOC. 46(9):531���535 (1957)

International Publication No. WO 2014/182620 to Wu et al.

Lund et al., The Kinetics of Atropine and Apoatropine in Aqueous Solutions, ACTA CHEM. SCAND. 22:3085-3097 (1968)

McBrien et al., Point-Counterpoint. How does atropine exert its anti-myopia effects?, OPHTHALMIC & PHYSIOL. OPT. 33:373���378 (2013)

U.S. Patent Publication No. 2007/0254914 to Wu et al.

Chua et al., Atropine for the Treatment of Childhood Myopia, OPHTHALMOLOGY 113(12):2285���2291 (2006)

Shih et al., An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression, ACTA OPHTHALMOL. SCAND. 79:233���236 (2001)

Lee et al., Prevention of Myopia Progression with 0.05% Atropine Solution, J. OCUL. PHARMACOL. & THER. 22(1):41���46 (2006)

Fang et al., Prevention of Myopia Onset with 0.025% Atropine in Premyopic Children, J. OCUL. PHARMACOL. & THER. 26(4):341���345 (2010)

Shih et al., Effects of Different Concentrations of Atropine on Controlling Myopia in Myopic Children, J. OCUL. PHARMACOL. & THER. 15(1):85���90 (1999)

Wu et al., The Long-Term Results of Using Low-Concentration Atropine Eye Drops for Controlling Myopia Progression in Schoolchildren, J. OCUL. PHARMACOL. & THER. 27(5):461���466 (2011)

Chia et al., Atropine for the Treatment of Childhood Myopia: Changes after Stopping Atropine 0.01%, 0.1% and 0.5%, AM. J. OPHTHALMOL. 157(2):451���457.e1 (2014)

Zvirblis et al., The Kinetics of the Hydrolysis of Atropine, J. AM. PHARM. ASSOC. 45(7): 450���454 (1956)

USP 24 Official Monographs / Atropine, THE UNITED STATES PHARMACOPEIA 177-180 (2000)

John D. Mullins & Gerald Hecht, Pharmaceutical Necessities and Ophthalmic Preparations, in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, VOLUME II 1380���1416, 1563���1576 (Alfonso R. Gennaro ed., 19th ed. 1995)

Drugs@FDA: FDA-Approved Drugs: AKORN NDA 206289, U.S. FDA, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206289

Application Number: 206289Orig1s000 Summary Review, U.S. FDA CTR. FOR DRUG EVALUATION & RES. (July 18, 2014)

Akorn Atropine CareTM (atropine sulfate ophthalmic solution), Advertisement Rev. 08/11

Akorn Atropine CareTM (Atropine Sulfate Ophthalmic Solution, 1%), Product Label Rev. 06/08

Schier et al., Preparing for Chemical Terrorism: Stability of Injectable Atropine Sulfate, ACAD. EMERG. MED. 11(4):329���334 (2004)

European Patent Publication No. 0332826 to Tashma

Anschel et al., Parenteral Formulation VI: Hydrolytic Degradation of Esters in Parenteral Solutions, BULLETIN PARENTER. DRUG ASSOC. 26(6):271���289 (1972)

Sumie Yoshioka & Valentino J. Stella, STABILITY OF DRUGS AND DOSAGE FORMS 228 (2002)

Ann E. Mair & G. Smith, The Detection of Atropine and Its Degradation Products by Thin-Layer Chromatography, J. CLIN. PHARM. 2:101-104 (1977)

Parmar et al., The solution, solid state stability and kinetic investigation in degradation studies of lercanidipine: study of excipients compatibility of lercanidipine, PHARM. DEV. TECHNOL. 17(6):730-740 (2011)

Deliang Zhou et al., Chapter 5 ��� Drug Stability and Degradation Studies, in DEVELOPING SOLID ORAL DOSAGE FORMS PHARMACEUTICAL THEORY AND PRACTICE 87-124 (Yihong Qiu et al. eds., 2009)

R.B. Taylor & A.S. Shivji, A critical appraisal of drug stability testing methods, PHARM. RES. 4(3):177-80 (1987)

U.S. Patent No. 5,716,952 to WoldeMussie et al.

U.S. Patent Publication No. 2012/0015035 to Wildsoet et al.

Garcia-Valldecabres et al., pH Stability of ophthalmic solutions, OPTOMETRY 75(3):161���168 (2004)

Lallemand et al., Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb, J. DRUG DELIV. 2012:1���16 (2012)

Erica L. Fletcher & Noel A. Brennan, The effect of solution tonicity on the eye, CLIN. & EXP. OPTOM. 76.1:17-21 (1993)

U.S. Patent No. 10,842,787 File History - Part 1

U.S. Patent No. 10,842,787 File History - Part 2

U.S. Patent No. 10,842,787 File History - Part 3

U.S. Patent No. 10,842,787 File History - Part 4

U.S. Patent No. 10,842,787 File History - Part 5

Pfannkoch, The Preparation of Buffers and Other Solutions: A Chemist���s Perspective, MOLECULAR BIOLOGY PROBLEM SOLVER: A LABORATORY GUIDE Ch. 3:31���47 (Alan S. Gerstein ed., 2001)

HANDBOOK OF PHARMACEUTICAL EXCIPIENTS 5���7, 193���196, 281���284, 351���352, 741���742, 984���989 (Raymond C. Rowe et al. eds., 7th ed. 2012) - Part 1

HANDBOOK OF PHARMACEUTICAL EXCIPIENTS 5���7, 193���196, 281���284, 351���352, 741���742, 984���989 (Raymond C. Rowe et al. eds., 7th ed. 2012) - Part 2

Waterman et al., Hydrolysis in Pharmaceutical Formulations, PHARM. DEV. & TECH. 7(2):113���146 (2002)

Certified English Translation of Yuanda Wen, Preparation and Clinical Curative Effects of 0.05% Atropine Sulfate Eye Drops, CHINA PHARMACIST 11(2):194���196 (2008)

M. R. W. Brown & D. A. Norton, The Preservation of Ophthalmic Preparations, J. SOC. COSMETIC CHEMISTS 16:369���393 (1965)

Certified English Translation of CN 101049287A to Wu Peichang et al.

Rajpal et al., Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence, PATIENT PREFER ADHERENCE 8:925���31 (2014)

Chowhan et al., Ophthalmic Preparations, in REMINGTON: THE SCIENCE & PRACTICE OF PHARMACY 907-929 (22d ed. 2013)

Kirchhoff et al., Analysis of atropine, its degradation products and related substances of natural origin by means of reversed-phase high-performance liquid chromatography, J. CHROMATOGRAPHY A 1046:115���120 (2004)

PB Patel et al., Ophthalmic Drug Delivery System: Challenges and Approaches, SYSTEMATIC REVIEWS IN PHARMACY 1(2):113���120 (2010)

International Publication No. WO 2012/161655 to Donald Tan and Wei Han Chua

U.S. Patent Publication No. 2012/0203161 to Herekar

English Translation of Jinshen Li, Preparation and Quality Control of 0.04% Atropine Sulfate Eye Drops, CHINA PHARMACY 17(2):111���113 (2006)

John D. Mullins & Gerald Hecht, Tonicity, Osmoticity, Osmolality and Osmolarity and Stability of Pharmaceutical Products, in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, VOLUME I 613���627, 639���647 (Alfonso R. Gennaro ed., 19th ed. 1995)